Co‐Treatment With rhBMP‐2 and Rapamycin Modulates Osteogenesis–Adipogenesis Balance to Enhance Aged Bone Regeneration
Advanced Science · 2026
DOI: 10.1002/advs.202521619 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Zirui He und 7 weiteren Autor:innen. Beteiligte Einrichtung: The State Key Laboratory of Bioreactor Engineering, Key Laboratory for Ultrafine Materials of Ministry of Education, Frontiers Science Center for Mat…. Hauptthemen laut MEDLINE: Bone Morphogenetic Protein 2, Bone Regeneration, Osteogenesis, Adipogenesis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic Science Center Project of National Natural Science Foundation of China, National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Recombinant human bone morphogenetic protein 2 (rhBMP‐2) is a well‐established osteoinductive agent used in clinical practice. In this study, rhBMP‐2 is found to exacerbate the imbalance between osteogenesis and adipogenesis in senescent bone marrow stromal cells (BMSCs), resulting in excess adipocytes (eADs) accumulation and a diminished osteogenic response. However, the role of eADs in age‐related bone repair deficits remains unclear. Our findings indicate that eADs within the aged microenvironment contribute to impaired bone regeneration by promoting BMSC senescence and suppressing osteogenic differentiation. To address this issue, we investigated the feasibility of regulating the abnormal differentiation of senescent BMSCs to enhance aged bone regeneration. Based on this, a novel energy‐supplying hydrogel system (PEGSN‐PGA/rhBMP‐2/Rapa, PBR) suitable for the aged regenerative microenvironment and with excellent bone integration performance is designed for local minimally invasive treatment of aged bone defects. This system effectively regulates the abnormal differentiation of senescent BMSCs, maintains the cell cycle process, and retains the regenerative potential for bone repair in the senescent microenvironment. This study presents a novel strategy for the treatment of rhBMP‐2‐mediated bone degenerative diseases and offers a pioneering perspective on the interplay among adipogenesis, cellular senescence, and bone regeneration during the aging process
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The State Key Laboratory of Bioreactor Engineering, Key Laboratory for Ultrafine Materials of Ministry of Education, Frontiers Science Center for Materiobiology and Dynamic Chemistry, East China University of Science an…
ORCID-Profile: Yuanman Yu, Yuan Yuan
Förderung
- Basic Science Center Project of National Natural Science Foundation of China
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- The Key Program of National Natural Science Foundation of China Regional Joint Funds
Zitieren
APA
He, Z., Bai, X., Xie, F., Wang, X., Zhang, F., Yu, Y., Yuan, Y., & Liu, C. (2026). Co‐Treatment With rhBMP‐2 and Rapamycin Modulates Osteogenesis–Adipogenesis Balance to Enhance Aged Bone Regeneration. Advanced Science. https://doi.org/10.1002/advs.202521619
Vancouver
He Z, Bai X, Xie F, Wang X, Zhang F, Yu Y, et al. Co‐Treatment With rhBMP‐2 and Rapamycin Modulates Osteogenesis–Adipogenesis Balance to Enhance Aged Bone Regeneration. Advanced Science. 2026. doi:10.1002/advs.202521619
BibTeX
@article{He2026,
author = {He, Zirui and Bai, Xiaoqiao and Xie, Fangru and Wang, Xuan and Zhang, Fan and Yu, Yuanman and Yuan, Yuan and Liu, Changsheng},
title = {Co‐Treatment With rhBMP‐2 and Rapamycin Modulates Osteogenesis–Adipogenesis Balance to Enhance Aged Bone Regeneration},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202521619}
}
EUVIMED